Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2023-11-14 AGM Information
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
关于召开2023年第二次临时股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2023 second extraordinary general meeting of shareholders (临时股东大会) of Chengdu Oukang Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items for shareholder approval, and procedural information. It does not contain financial statements or detailed financial analysis. The document is an announcement related to a shareholders' meeting rather than the meeting materials themselves or the voting results. The document length is 3578 characters, which is relatively short and consistent with a meeting notice. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or related to the Annual or Extraordinary General Meeting, including notices of meetings.
2023-11-14 Chinese
董事、监事和高级管理人员持股变动管理制度
Board/Management Information Classification · 95% confidence The document is titled as a management system for shareholding changes by directors, supervisors, and senior management of Chengdu Oukang Pharmaceutical Co., Ltd. It details rules and procedures for managing shareholding and share transfers by company insiders, including reporting, disclosure, restrictions, and penalties. It is a formal announcement of a governance policy or internal management system rather than a financial report, audit, or earnings release. It does not contain financial statements or results, nor is it a notice of voting results or a proxy statement. The content fits best under Board/Management Information (MANG) as it relates to management and board members' shareholding management rules and internal governance. The document length is about 4720 characters, which is substantive and not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2023-11-14 Chinese
关于设立董事会审计委员会并选举委员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the establishment of the Board Audit Committee and the election of its members. It details the governance structure changes, committee composition, and related procedural rules. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory certifications. The content focuses on board/management information related to governance and committee formation. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Confidence is high due to clear governance-related content.
2023-11-14 Chinese
内部控制制度
Governance Information Classification · 95% confidence The document is a detailed internal control system policy issued by the board of directors of Chengdu Oukang Pharmaceutical Co., Ltd. It includes comprehensive descriptions of internal control objectives, principles, requirements, control activities, supervision, and information disclosure. The document is signed by the board and dated November 15, 2023. It is not a financial report, earnings release, or announcement of voting results. It is a governance-related document detailing internal rules and control systems of the company. Therefore, it fits best under Governance Information (CGR). The document length and content confirm it is the actual policy document, not just an announcement or summary.
2023-11-14 Chinese
股东大会议事规则
Governance Information Classification · 95% confidence The document is titled "成都欧康医药股份有限公司股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting of Chengdu Oukang Pharmaceutical Co., Ltd." It details the rules, procedures, and governance related to the conduct of shareholders' meetings, including the powers of the shareholders' meeting, the process for convening meetings, proposal submissions, voting procedures, and other governance-related matters. It is not a report of financial results, audit, or earnings, nor is it an announcement of voting results or a notice of dividend. It is a governance document outlining internal rules and procedures for shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length is substantial (over 12,000 characters) and contains detailed governance rules, not just an announcement or summary, so it is not an RPA or RNS. Hence, the classification is CGR with high confidence.
2023-11-14 Chinese
融资与对外担保管理办法
Governance Information Classification · 95% confidence The document is titled "成都欧康医药股份有限公司融资与对外担保管理办法" which translates to "Chengdu Oukang Pharmaceutical Co., Ltd. Financing and External Guarantee Management Measures." It is a detailed internal governance document outlining the company's policies and procedures for financing and providing external guarantees. The document includes sections on approval processes, risk management, disclosure obligations, and responsibilities of company personnel. It references the company's board meetings and shareholder meetings for approval of these policies. There is no financial data, earnings information, or report publication announcement. The document is a governance-related policy document rather than a financial report or announcement. Therefore, it fits best under Governance Information (CGR). The document length is over 5,000 characters and contains substantive content, so it is not a mere announcement or regulatory filing. Hence, the classification is CGR with high confidence.
2023-11-14 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.